Candida bloodstream infections in Serbia: First multicentre report of a national prospective observational survey in intensive care units

Summary Candida bloodstream infections (BSI) are a significant cause of mortality in intensive care units (ICU), hereof the prospective 12‐months (2014‐2015) hospital‐ and laboratory‐based survey was performed at the Serbian National Reference Medical Mycology Laboratory (NRMML). Candida identificat...

Full description

Saved in:
Bibliographic Details
Published in:Mycoses 2018-02, Vol.61 (2), p.70-78
Main Authors: Arsić Arsenijević, Valentina, Otašević, Suzana, Janić, Dragana, Minić, Predrag, Matijašević, Jovan, Medić, Deana, Savić, Ivanka, Delić, Snežana, Nestorović Laban, Suzana, Vasiljević, Zorica, Hadnadjev, Mirjana
Format: Article
Language:English
Subjects:
Candida
Candida albicans
Candida bloodstream infections
Epidemiology
Flucytosine
Intensive care
intensive care unit
Intensive care units
Itraconazole
Laboratories
Mass spectroscopy
Mortality
Neonates
outcome
Patient admissions
Serbia
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Candida bloodstream infections (BSI) are a significant cause of mortality in intensive care units (ICU), hereof the prospective 12‐months (2014‐2015) hospital‐ and laboratory‐based survey was performed at the Serbian National Reference Medical Mycology Laboratory (NRMML). Candida identification was done by a matrix‐assisted laser desorption/ionisation time‐of‐flight mass spectrometry and a susceptibility test, according to the Clinical and Laboratory Standards Institute methodology. Among nine centres (265 beds; 10 820 patient admissions), four neonatal/paediatric (NICU/PICUs) and five adult centres (ICUs) participated, representing 89 beds and 3446 patient admissions, 166 beds and 7347 patient admissions respectively. The NRMML received 43 isolates, 17 from NICU/PICUs and 26 from adult ICUs. C. albicans dominated highly in NICU/PICUs (~71%), whereas C. albicans and C. parapsilosis were equally distributed within adults (46%, each), both accounting for ~90% of received isolates. The resistance to itraconazole and flucytosine were 25% and 2.4% respectively. In addition, the 2 C. albicans were azole cross‐resistant (4.6%). The overall incidence of CandidaBSI was ~3.97 cases/1000 patient admissions (4.93 in NICU/PICU and 3.53 in adult ICU). The 30‐day mortality was ~37%, most associated with C. tropicalis and C. glabrataBSI. Data from this national survey may contribute to improving the Balkan and Mediterranean region epidemiology of CandidaBSI within ICUs.
ISSN:0933-7407
1439-0507
DOI:10.1111/myc.12700